Natixis Advisors LLC Takes $310,000 Position in Artivion, Inc. (NYSE:AORT)

Natixis Advisors LLC bought a new position in shares of Artivion, Inc. (NYSE:AORT) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 10,838 shares of the company’s stock, valued at approximately $310,000.

Other hedge funds also recently added to or reduced their stakes in the company. Amundi increased its holdings in Artivion by 174.8% in the fourth quarter. Amundi now owns 18,288 shares of the company’s stock valued at $553,000 after buying an additional 11,634 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Artivion during the 4th quarter valued at about $275,000. Charles Schwab Investment Management Inc. increased its stake in shares of Artivion by 2.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 358,192 shares of the company’s stock valued at $10,241,000 after purchasing an additional 8,343 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares during the period. Finally, Arcadia Investment Management Corp MI acquired a new stake in Artivion in the fourth quarter valued at approximately $43,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Stock Performance

NYSE:AORT opened at $24.26 on Friday. The firm has a market capitalization of $1.02 billion, a PE ratio of -1,212.80 and a beta of 1.79. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The business’s fifty day moving average price is $27.58 and its 200 day moving average price is $27.61. Artivion, Inc. has a 12 month low of $19.36 and a 12 month high of $32.33.

Artivion (NYSE:AORT) last posted its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million during the quarter, compared to analysts’ expectations of $100.82 million. On average, sell-side analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AORT has been the topic of several research analyst reports. Needham & Company LLC dropped their target price on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Stifel Nicolaus lowered their price objective on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Finally, JMP Securities reissued a “market outperform” rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $31.40.

Insider Buying and Selling at Artivion

In other Artivion news, CEO James P. Mackin sold 42,156 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the sale, the chief executive officer now directly owns 663,882 shares in the company, valued at approximately $18,130,617.42. The trade was a 5.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jean F. Holloway sold 18,020 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total transaction of $425,452.20. Following the completion of the transaction, the senior vice president now directly owns 197,184 shares of the company’s stock, valued at approximately $4,655,514.24. This trade represents a 8.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,799 shares of company stock valued at $2,356,223 in the last ninety days. Insiders own 8.10% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.